

Clinical trials of otamixaban

TrialResults-center www.trialresultscenter.org

1 acute coronary syndrome

Trial	Treatments	Patients	Trials design and methods
otamixaban vs unfractionated heparin			
SEPIA-ACS1 TIMI 42 , 2009 [NCT00317395] n=2792/449 follow-up: 7 days	otamixaban 5 doses (008 mg/kg bolus followed by 0.035, 0.070, 0.105, 0.140, 0.175 mg/kg/h) versus Heparin+eptifibatide	patients with non-ST-elevation acute coronary syndromes	Parallel groups double blind 36 countries

More details and results :

- antithrombotics for acute coronary syndrome in all type of patients at <http://www.trialresultscenter.org/go-Q24>
- anticoagulant for acute coronary syndrome in All ACS (including AMI) at <http://www.trialresultscenter.org/go-Q167>
- direct factor Xa inhibitors for acute coronary syndrome in all type of patients at <http://www.trialresultscenter.org/go-Q345>
- direct oral anticoagulant (DAO) for acute coronary syndrome in all type of patients at <http://www.trialresultscenter.org/go-Q480>

References

SEPIA-ACS1 TIMI 42, 2009:

Sabatine MS, Antman EM, Widimsky P, Ebrahim IO, Kiss RG, Saaiman A, Polasek R, Contant CF, McCabe CH, Braunwald E Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial. Lancet 2009 Aug 28; [19717184] [10.1016/S0140-6736\(09\)61454-9](https://doi.org/10.1016/S0140-6736(09)61454-9)